Background Psoriasis is a common skin condition driven by increased expression of interleukin (IL)-17. Langerhans cells (LCs) are epidermal dendritic cells that regulate cutaneous immune responses. Within the uninvolved skin of patients with psoriasis, LCs display impaired migration from the epidermis. Objectives To investigate the role of keratinocytes (KCs) in the regulation of LC function and the response of KCs to IL-17. Methods KCs were cultured from the uninvolved skin of patients with psoriasis and healthy individuals with or without IL-17 treatment and the conditioned medium examined for its ability to alter LC function in an ex vivo human skin explant model. Furthermore, we examined the effect of IL-17 on LC mobilization in psoriasis by neutralizing IL-17 in the same skin explant model. Results Conditioned medium from psoriasis KCs inhibited LC migration in healthy skin. Moreover, conditioned medium from healthy KCs treated with IL-17 also inhibited healthy LC migration. Finally, neutralizing IL-17 in psoriasis skin resulted in enhanced LC migration. Conclusions Collectively, these data suggest that an altered KC secretome, driven by increased expression of IL-17, is responsible for impaired LC migration in the uninvolved skin of patients with psoriasis.
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What's already known about this topic?
• Langerhans cells (LCs) are the dendritic cells of the epidermis and regulate the cutaneous immune response.
• LC migration is impaired in the uninvolved skin of patients with early-onset chronic plaque psoriasis.
• Interleukin (IL)-17 is a cytokine that is involved in the pathogenesis of psoriasis.
• We have recently shown that IL-17 inhibits LC migration in a healthy human ex vivo epidermal explant model.
What does this study add?
• Conditioned media generated from psoriasis, but not healthy, keratinocytes (KCs), inhibits LC migration.
• Conditioned media generated from healthy KCs treated with IL-17 also inhibits LC migration.
• This suggests that KCs, in response to increased expression of IL-17, are responsible for secreting a factor that alters LC function.
• In an ex vivo psoriasis explant model addition of neutralizing anti-IL-17 antibody restores LC migration.
What is the translational message?
• This study provides further evidence that IL-17 is a key cytokine driving the epidermal changes in psoriasis and is thus an attractive target for therapy.
• The inhibitory factor produced by KCs under IL-17 control, once identified, is also a potential druggable target.
Psoriasis is a common inflammatory skin condition affecting approximately 2% of the U.K. population. Langerhans cells (LCs) are the dendritic cells of the epidermis. After encountering a pathogen or allergen, LCs migrate from the epidermis to the lymph nodes where they regulate immune responses. 1, 2 Furthermore, epidermal LCs also regulate immunity in the skin by interaction with T regulatory cells. 3 We have shown previously that in the uninvolved skin (PN) of patients with early-onset chronic plaque psoriasis (presenting before age 40 years) there is impaired LC migration in vivo. 4 Furthermore, we have replicated these findings using an ex vivo epidermal explant culture model where healthy epidermis shows an approximately 20% reduction in LCs compared with no reduction in LC frequency in PN. 5 The interleukin (IL)-17/IL-23 pathway appears to be integral to the pathogenesis of psoriasis, and monoclonal antibody therapies targeting these cytokines have proved to be highly successful. 6, 7 We have recently shown that IL-17 treatment completely inhibits LC mobilization in both human and mouse skin ex vivo. 8 IL-17 can act directly on keratinocytes (KCs), resulting in upregulation of cytokines and antimicrobial peptides. [9] [10] [11] [12] Here, we have examined the effects of KC secreted factors from healthy skin and PN on epidermal LC migration. We also investigated the effect of IL-17 on healthy KCs in addition to the effect of IL-17 neutralization on LC migration in psoriasis skin.
Patients and methods

Participants and skin samples
Participants were aged between 18 and 65 years and were divided into the following groups: healthy with no history of skin disease (healthy group) and volunteers with earlyonset chronic plaque psoriasis (psoriasis group). The psoriasis group had not received any systemic or phototherapy for at least a month before participation. Participants provided up to four 6-mm punch biopsies, taken under local 1% lignocaine anaesthetic, from sun-protected buttock skin (in the case of the psoriasis group this was PN). The study was approved by the NRES Committee Northwest -Greater Manchester West Research Ethics Committee (13/NW/ 0867) and was conducted according to the Declaration of Helsinki and all participants provided written, informed consent.
Keratinocyte culture
KCs were isolated from 6-mm skin biopsies by a method described previously, 13 with slight modifications. Briefly, the skin was floated on dispase overnight at 4°C. 
Generation of keratinocyte conditioned medium and lysates
To generate KC conditioned medium, cells were allowed to reach confluence in a 12-well plate and fresh complete EpiLife medium was added to each well. In some experiments KCs received the addition of 100 ng mL À1 recombinant human IL-17 (R&D Systems Europe, Abingdon, U.K.), or bovine serum albumin (BSA) vehicle control (Sigma-Aldrich). After 6 days the media were harvested and centrifuged at 200 g, and the conditioned medium stored at À80°C for future use in explant assays and for analysis by enzyme-linked immunosorbent assay (ELISA) and Proteome Profiler Array (R&D Systems). KCs were lysed from the plate using 350 lL per well of lysis buffer (Thermo Fisher Scientific) containing 1% bmercaptoethanol and stored at À80°C for RNA extraction.
Epidermal explant assay
Between two and four skin biopsies were collected from each participant and epidermal sheets removed as described previously. 5 One was fixed in acetone immediately (T 0 control). The others were cultured by floating on 500 lL RPMI medium (Thermo Fisher Scientific) containing 10% FCS (RPMI/FCS) in a 24-well plate for 24 h (T 24 ) before fixing. In some experiments, epidermal explants were cultured with previously generated KC conditioned medium. In these experiments complete EpiLife medium was used in place of RPMI for control cultured sheets. In some experiments 100 ng mL À1 recombinant IL-17 and/or 1-2 lg mL À1 neutralizing goat antihuman IL-17
antibody was added into the culture media (both R&D Systems).
Whole skin explant assay
From each participant the epidermal sheet was removed from one biopsy and isolated and fixed (T 0 ) as described previously. 5 Another biopsy from the same participant was floated on 500 lL RPMI/FCS in a 24-well plate for 24 h. For the psoriasis group, biopsies were also incubated with 2 lg mL À1 neutralizing goat antihuman IL-17 antibody (or normal goat serum control) in 500 lL RPMI/FCS. After 24 h, epidermal sheets were isolated as described previously (T 24 ).
Analysis of epidermal sheets
Epidermal sheets from explant assays were stained for LCs using CD1a as a marker, as described previously. 5 Fifty fields were counted in the central portion of each epidermal sheet. The frequency of LCs was expressed as cells per mm 2 and migration was examined as the percentage decrease in LC frequency in the T 24 epidermal sheets compared with the T 0 from the same participant, as described previously.
Proteome profiler array
Healthy and psoriasis KC conditioned media samples from multiple participants were pooled and analysed using Human XL Cytokine Proteome Profiler and the Human Chemokine Proteome Profilers (both R&D systems) according to the manufacturer's instructions.
Enzyme-linked immunosorbent assay
Keratinocyte conditioned media were analysed for chemokine (C-C motif) ligand 20 (CCL20), IL-8 and matrix metalloproteinase (MMP)-9 by DuoSet ELISA (R&D Systems), performed according to the manufacturer's instructions.
Quantitative polymerase chain reaction
RNA was extracted from cell lysates using an RNA isolation kit, followed by cDNA conversion using a High Capacity RNA-to-cDNA kit (both Thermo Fisher Scientific) according to
Conditioned medium from psoriasis keratinocytes (KCs) inhibits Langerhans cell (LC) migration in a healthy epidermal explant model. Conditioned medium was generated from healthy (H) and psoriasis (PS) KCs (n = 4 per group). Biopsies were obtained from uninvolved psoriasis skin and the epidermis was isolated and fixed immediately (T 0 ) or cultured for 24 h (T 24 ). The mean density of LCs in T 24 epidermal sheets cultured with (a) EpiLife or (b) healthy KC conditioned media, compared with T 0 , n = 7. Epidermal sheets were prepared from two biopsies from healthy individuals and one was fixed immediately (T 0 ) and the other cultured for 24 h. The mean density of LCs in T 24 epidermal sheets cultured with (d) EpiLife, (e) healthy KC conditioned medium and (f) PS KC conditioned medium compared with T 0 , n = 6 per group. The significance of differences between the T 0 and the T 24 samples was analysed by paired t-test. The percentage migration levels in the T 24 epidermal sheet compared with the T 0 for each group for psoriasis explants (c) and healthy explants (g). The statistical significance of differences was analysed by t-test (c) or one-way ANOVA (g); ***P < 0Á01. 
Results
Psoriasis keratinocytes inhibit Langerhans cell migration in healthy skin
We have demonstrated previously that, in PN, LC migration is impaired. 4, 5 To examine whether healthy KC factors can restore LC migration in PN we cultured epidermal explants of PN using conditioned media generated from healthy KCs (Fig. 1 ). There was little or no LC migration in psoriasis samples in this model; the frequency of LCs in the EpiLife medium T 24 group did not differ significantly from the T 0 control (Fig. 1a) . Healthy KC conditioned media had no effect on PN, that is no significant difference in LC frequency was found between epidermal sheets cultured in EpiLife control or healthy KC conditioned medium (Fig. 1b) , and did not alter the percentage migration; 3Á4 AE 4Á5% and 2Á9 AE 3Á7% for EpiLife control and healthy KC conditioned medium, respectively (Fig. 1c) .
Subsequently, we examined whether secreted factors from psoriasis KCs altered LC migration in healthy skin by culturing healthy epidermis with conditioned media from psoriasis KCs derived from PN. LC frequency in healthy skin was significantly lower than in the T 0 control after 24- ; Fig. 1e ). LC migration levels were not significantly different between the EpiLife control and healthy KC conditioned medium cultured epidermal sheets (Fig. 1g) , and levels of LC migration were comparable with that previously seen in individuals with healthy skin. 5 However, when healthy epidermal sheets were cultured with psoriasis KC conditioned media, there was no reduction in LC frequency in the T 24 epidermal sheet (Fig. 1f) and the proportion of LCs migrating was significantly reduced to 2Á1 AE 3Á0% (Fig. 1g) .
Interleukin-17 induces changes in healthy keratinocytes
As we have previously shown that the psoriasis-associated cytokine IL-17 inhibits LC migration in healthy skin, 8, 14 we sought to examine IL-17-induced changes in healthy KCs. KCs from multiple donors were treated with IL-17 or BSA control and analysed for changes in genes and proteins associated with psoriasis. Gene expression data were expressed as the mean Each line represents matched BSA and IL-17 for each KC sample, n = 6. The statistical significance of differences between BSA and IL-17 groups was analysed by paired t-test; *P < 0Á05, **P < 0Á01.
fold change in each sample against the mean value for the BSA control. KCs treated with IL-17 showed significantly upregulated levels of DEFB4, CCL20 and IL-8 (Fig. 2a, d and e) whereas MMP-9 secretion was significantly decreased (Fig. 2c) .
We have shown previously that recombinant human IL-17 impairs LC migration in the explant model. 8 Therefore,
we went on to investigate whether IL-17 can affect the ability of KCs to inhibit LC migration in this model by culturing healthy epidermis with conditioned media generated from IL-17 treated KCs. To ensure that any effect of IL-17 on LC migration was because of the downstream effects of IL-17 on KCs and not residual recombinant IL-17 in the KC conditioned media, we employed a neutralizing IL-17 antibody in each of the epidermal explant culture conditions. In our previous study LC migration was completely inhibited (0Á9 AE 1Á7%) when epidermal sheets were cultured with 100 ng mL À1 IL-17. 8 The same concentration of recombinant IL-17 was used in the current study to treat KCs for generation of conditioned media, and to treat healthy epidermal explants directly in the presence of a neutralizing IL-17 antibody as a control for the LC migration experiments. This control group had a lower frequency of LCs compared with T 0 (Fig. 3c ) and percentage LC migration levels in this group were in the normal range (19Á6 AE 10Á5%; Fig. 3d ), demonstrating that the antibody used effectively neutralizes this concentration of IL-17 in this model. When healthy epidermal sheets from the same individuals were incubated with conditioned media from KCs treated with vehicle control (BSA; Fig. 3a) there was a significant reduction in LC density equivalent to 22Á9 AE 1Á0% migration (Fig. 3d) . However, when healthy epidermal sheets were incubated with conditioned medium from IL-17 treated KCs, LC frequency was reduced to a lesser extent and migration levels were reduced by half to 10Á4 AE 7Á7% (Fig. 3d) . Thus, the decrease in LC migration observed in the epidermal sheets cultured with IL-17-treated healthy KC conditioned medium is a consequence of alterations in the KC secretome in response to IL-17 and not residual recombinant IL-17 in the conditioned medium.
No difference in interleukin-17 receptor expression in psoriasis keratinocytes from uninvolved skin
Next, we examined the expression of genes directly related to the IL-17 pathway in psoriasis vs. healthy KCs. Firstly, we examined levels of IL-17 receptor subunits but they did not differ between healthy and psoriasis KCs (Fig. 4a-e) . To determine whether psoriasis KCs were upregulating and maintaining IL-17 downstream signalling pathways in response to increased exposure to IL-17 in vivo, we examined gene expression levels of CEBPB (gene encoding CCAAT/enhancer-binding protein-b; Fig. 4f ) and NFKBIZ (gene encoding the protein NF-kappa-B inhibitor f; Fig. 4g ). However, there were no significant differences between the groups.
Conditioned media from healthy and psoriasis keratinocytes have similar cytokine profiles
As conditioned medium from psoriasis KCs inhibits LC migration, we wanted to examine the cytokine and chemokine profile. To do this we utilized an XL cytokine (Fig. 5a ) and a chemokine (Fig. 5b ) proteome profiler to analyse pooled healthy vs. pooled psoriasis KCs. There were no large differences in cytokine and chemokine production between healthy and psoriasis cells. To validate the results of the proteome The percentage LC migration in the T 24 groups compared with the T 0 group. The statistical significance of differences was analysed by paired t-test (a, b, c) or one-way ANOVA followed by Tukey post-hoc test (d), *P < 0Á05, ***P < 0Á001, ns = not significant.
profiler arrays, several proteins were selected for individual samples to be tested quantitatively by ELISA (MMP-9, Fig. 5c ; CCL20, Fig. 5d ; IL-8, Fig. 5e ; and CCL5, Fig. 5f ) but no significant differences were found.
Blocking interleukin-17 leads to improvements in Langerhans cell migration in a whole skin explant model
As we have demonstrated that the changes in psoriasis KCs responsible for impairing LC migration are likely driven by exposure to increased IL-17 in vivo, and as previous literature suggests that the source of IL-17 in psoriatic skin is dermal cells, 15 we next analysed whether addition of anti-IL-17 neutralizing antibody to whole (epidermis and dermis) cultured PN would restore LC migration. Initially we analysed the level of LC migration in the healthy whole skin explant model and the mean percentage LC migration was 29Á6% (Fig. 6a) . LC migration in whole PN varied from 0% to 19Á2% but on average was significantly lower than that for healthy skin (11Á2%; Fig. 6a ). When psoriasis explants were treated with normal goat serum control alone, there was no significant reduction in LC density in the T 24 epidermal sheet compared with the T 0 control (Fig. 6c) . In contrast, when explants were cultured in the presence of neutralizing anti-IL-17 antibody, there was a significant reduction in LC density in the T 24 epidermis (Fig. 6d) . When comparing the two groups as percentage LC migration, addition of neutralizing anti-IL-17 antibody led to a significant improvement in LC migration levels (to 24Á61%; Fig. 6b ).
Discussion
Our current findings suggest that KCs play an important role, and may be solely responsible, for the impaired LC migration observed in the PN skin in chronic plaque psoriasis. Our previous studies have shown that there is no obvious impairment of blood monocyte-derived LCs. 16 The implication is rather that impairment of LC migration is associated with an altered epidermal phenotype. The data presented here are consistent with that view. Conditioned medium from psoriasis KCs, but not from healthy KCs, inhibited LC migration in an explant model incorporating normal epidermis. These data provide evidence, for the first time, that products of KCs in PN sites of patients with psoriasis are able to impair LC migration.
As we know that IL-17 inhibits LC migration, 8 we sought to characterize the effects of IL-17 on KCs, in order to establish whether IL-17 was responsible for driving the observed changes in psoriasis KCs. We observed changes in response to The statistical significance of differences between groups was analysed using an unpaired t-test, but no significant differences were found.
IL-17, including elevated expression of DEFB4, the gene encoding b-defensin 2, and increased secretion of CCL20, consistent with previous studies. 9, 17 Overexpression of b-defensin 2 and CCL20, chemoattractants for chemokine (C-C motif) receptor 6, expressed by immature LCs, [18] [19] [20] may result in retention of LCs within the epidermis. Treatment with IL-17 resulted in decreased secretion of MMP-9, a protease required for migration to the dermis through the basement membrane 21, 22 and thus a reduction in MMP-9 secretion could also contribute to impaired LC migration. We found here that treatment with IL-17 not only changed gene and protein expression, but also altered the phenotype of healthy KCs to function in a way comparable with psoriasis KCs, that is, that conditioned media generated from IL-17-treated healthy KCs inhibited healthy LC migration. This suggests that the altered function seen in psoriasis KCs is a consequence of increased IL-17 in the skin.
Recent data have shown that IL-17 downstream genes are also upregulated in PN, 11 confirming our findings that dysregulation of IL-17 signalling is also relevant in skin that appears clinically normal. It is unclear why PN skin appears clinically healthy despite responding to IL-17 and future studies should examine whether PN is simply exposed to less IL-17 compared with lesional skin, or whether there are regulatory mechanisms in place that prevent the formation of psoriasis plaques despite responsiveness to IL-17. In order to examine whether psoriasis KCs are more efficient at responding to IL-17, we examined the expression of IL-17 receptor subunits; however, no significant differences were found between cells from healthy and psoriasis donors. The implication is that psoriasis KCs do not have an increased capacity to respond to IL-17, and it is therefore more likely that altered function observed with psoriasis KCs is simply because of more IL-17 being available in the skin.
When investigating downstream mediators of IL-17 including CEBPB and NFKBIZ, genes which are upregulated in psoriasis, 12, 23, 24 exposure is fairly transient. Indeed, when comparing the healthy and psoriasis KC secretome we failed to see any differences in the cytokines and chemokines tested, including those upregulated by healthy KCs in response to IL-17. The interpretation is, therefore, that although the IL-17-induced upregulation of chemoattractants (such as b-defensin 2 and CCL20) and downregulation of MMP-9 may contribute to the impaired LC mobilization observed in vivo, it is not a cytokine or chemokine that is responsible for directly inhibiting LC migration in this model. The retained phenotype of psoriasis KCs to impair LC migration long after exposure to IL-17 could be because of alterations in the secretome of other classes of proteins or even molecules such as lipids. Future work is required to determine the factor, or factors, secreted by psoriasis KCs that impair LC migration, and furthermore how they are regulated by IL-17.
Although we have previously shown that IL-17 directly impairs healthy LC migration, 8 and we report here that IL-17
induces healthy KCs to secrete a factor that inhibits LC migration, there was a need to confirm that upregulation of IL-17 in PN skin is the mechanism responsible for impaired LC function. We found that neutralization of IL-17 resulted in the restoration of normal LC mobilization in PN, confirming that an IL-17-driven mechanism is responsible for altering LC function in psoriasis.
We have shown previously that anticytokine treatments restore LC migration in patients with psoriasis. 5 Further work should examine whether LC migration is restored in the skin of patients using anti-IL-17 therapies. As LCs pay a key role in orchestrating immune responses, 3 one theory is that the decreased ability of LCs to migrate from the skin to the lymph node may result in a lack of regulation of the immune response. It is currently unknown whether the function of LCs is also impaired in psoriasis plaques, but one study has demonstrated that there are increased numbers of activated LCs found at perilesional sites, 25 suggesting that LC migration may also be impaired here. Together our data have shown that the observed impairment in LC migration in the PN skin of chronic plaque psoriasis is the result of IL-17-driven changes in the phenotype and function of KCs, leading to changes in the KC secretome that impair LC function. (n = 6). The statistical significance of differences was analysed by unpaired (a) and paired (b, c and d) t-tests; **P < 0Á01, ***P < 0Á001.
